SCHEMBL4470946

SCHEMBL4470946

CCCCC/C=C/c1nc(CCOS(C)(=O)=O)c(C)o1

nearest known ligand 0.40

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 5/20 0.38
PPARG P37231 5/20 0.38
EPHX2 P34913 1/20 0.33
FAAH O00519 8/20 0.33
PRKCA P17252 1/20 0.33
CES1 P23141 2/20 0.32
LPAR3 Q9UBY5 1/20 0.31
DAGLA Q9Y4D2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4470949 1.00 PTPN1 (0.38) PTPN1PPARGEPHX2FAAHPRKCA
SCHEMBL3292591 0.91 PTPN1 (0.38) PTPN1PPARG
SCHEMBL3292593 0.91 PTPN1 (0.38) PTPN1PPARG
SCHEMBL4486636 0.88 PTPN1 (0.32) PTPN1PPARG
SCHEMBL4486633 0.88 PTPN1 (0.32) PTPN1PPARG
SCHEMBL4476003 0.86 PTPN1 (0.31) PTPN1PPARG
SCHEMBL4476004 0.86 PTPN1 (0.31) PTPN1PPARG
SCHEMBL4470337 0.83 PTPN1 (0.33) PTPN1PPARG
SCHEMBL4470341 0.83 PTPN1 (0.33) PTPN1PPARG
SCHEMBL4491659 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7557123-B2 Heterocyclic compound and medicinal use thereof KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2009-07-07 US disclosed
US-20040220215-A1 Novel heterocyclic compound and medicinal use thereof KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2004-11-04 US disclosed
EP-1403253-A1 NOVEL HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF Kyoto Pharmaceutical Industries, Ltd. (JP) 2004-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220215-A1 Novel heterocyclic compound and medicinal use thereof GPR119, INSR, GLP1R PTPN1 750/4885PPARG 6/4885EPHX2 3298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.